Cite
Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19).
MLA
Thilagar, Bright P., et al. “Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19).” Obstetrics & Gynecology, vol. 139, no. 4, Apr. 2022, pp. 616–18. EBSCOhost, https://doi.org/10.1097/AOG.0000000000004700.
APA
Thilagar, B. P., Ghosh, A. K., Nguyen, J., Theiler, R. N., Wick, M. J., Hurt, R. T., Razonable, R. R., & Ganesh, R. (2022). Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19). Obstetrics & Gynecology, 139(4), 616–618. https://doi.org/10.1097/AOG.0000000000004700
Chicago
Thilagar, Bright P., Aditya K. Ghosh, Jerome Nguyen, Regan N. Theiler, Myra J. Wick, Ryan T. Hurt, Raymund R. Razonable, and Ravindra Ganesh. 2022. “Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19).” Obstetrics & Gynecology 139 (4): 616–18. doi:10.1097/AOG.0000000000004700.